USTR Launches Section 301 Investigation into Germany's Persistent Underpayment for Innovative Pharmaceutical Products (June 18, 2026) — 9% Confidential-Pricing Discount + Draft 2027 Mandatory Patented-Medicine Rebate in Scope
The Office of the U.S. Trade Representative initiated a Section 301 investigation into Germany's pricing practices for innovative pharmaceuticals on June 18, 2026, alleging that Germany's persistent underpayment for innovative pharmaceutical products is unreasonable or discriminatory and burdens or restricts U.S. commerce. The investigation focuses on Germany's 9% price discount tied to pricing confidentiality and on draft 2026 German legislation that would add a mandatory rebate on patented medicines starting in 2027. The USTR public comment docket opens June 25, with submissions due by August 10 and a hearing scheduled for September 22, 2026. The investigation extends the most-favored-nation drug-pricing pressure President Trump applied to Lilly and Novo Nordisk under the TrumpRx framework toward European pricing regimes; if USTR finds Germany's practices harm US commerce, retaliatory tariffs on German pharmaceutical exports are among the available remedies — a meaningful threat to GLP-1 supply chains given Bachem and Boehringer Ingelheim's German manufacturing footprint.